Heart health

Identifying risk of heart disease requires advanced screening methods


Heart disease is the leading cause of death for women in United States, killing 299,578 women in 2017—or about 1 in every 5 female deaths.1

  • 1 in every 3 deaths in the US is related to CVD2
  • About 2,300 Americans die of CVD each day—one every 38 seconds2
  • Nearly half of all heart attack patients are found to have no prior risk that would indicate they are heading toward an attack2
  • Many of the risk factors contributing to CVD are modifiable—such as smoking, physical inactivity, and nutrition2
We are committed to helping you uncover your patient's potential hidden risks for heart attack and stroke.

symptomatic-education.jpg symptomatic-education.jpg symptomatic-education.jpg symptomatic-education.jpg

Advanced cardiometabolic solutions

Going beyond standard lipid panels to assess lipoprotein, apolipoprotein, inflammatory, metabolic, and genetic risk factors may provide deeper insights into the residual risk of your patients.

Our cardiovascular tests provide a more in-depth look at genetic risk factors and lifestyle factors, like smoking, diet, and stress to help you and your patients understand their cardiovascular health.

Advanced lipids

Going beyond standard lipid panels to assess lipoprotein and apolipoprotein risk factors may provide deeper insights into the residual risk of your patients. Patients who may benefit from advanced testing include those with:

  • Established CVD
  • Diabetes
  • Hypertension
  • Metabolic syndrome
  • Elevated LDL-C >=190 mg/dL
  • >=5% estimated ASCVD risk
  • Other traditional risk factors, including:
    • Age (men >45 years; post-menopausal women)
    • Family history of premature onset of CVD
    • Unhealthy diet, excessive alcohol intake, smoking, and/or stress
    • Obesity
    • Low HDL-C

Advanced inflammatory markers

Routine lipid screening plays an important role in cardiovascular risk assessment, but it may not adequately identify risk of adverse events. In fact, nearly 50% of all heart attacks and strokes occur in patients who had “normal” cholesterol levels.3 Evidence suggests that inflammation within the artery wall is a key contributor to residual risk for heart attack and stroke, contributing to both vulnerable plaque formation and to plaque rupture.

Inflammation can be easily measured with advanced testing to more fully assess cardiovascular risk. Monitoring a patient’s inflammatory status may help you to uncover hidden risk from early to advanced stages of cardiovascular disease. With deeper insights, you can take further action to help reduce your patient's cardiovascular risk.

Cardiogenetic

In many patients,the risk of CVD may be attributed to genetic polymorphisms and mutations. Quest Diagnostics offers cardiogenetic testing to aid in early diagnosis and earlier treatment for affected patients, as well as family members.

Familial hypercholesterolemia (FH) refers to a group of genetic defects resulting in severe elevations of blood cholesterol levels and increased risk of premature coronary heart disease (CHD). Cardio IQ® genetic testing for FH from Quest can help you make an early, specific diagnosis of FH so you can help your patients understand their risk.

Metabolic

Patients who have metabolic syndrome are at higher risk of multiple chronic conditions, including diabetes, coronary heart disease, and cancer, as well as stroke. Metabolic syndrome has become increasingly common: its prevalence has risen in every sociodemographic group, and today it is estimated that more than a third of adults in the United States have metabolic risk.4 Some factors contributing to metabolic syndrome are genetic, while others can be modified with lifestyle changes.

Heart failure

With the US population aging, prevalence of heart failure (HF) is projected to grow by 25% and associated direct costs by 215% by 2030.5

Patients who may be at risk for developing heart failure include those with:

  • Poorly controlled hypertension
  • Diabetes
  • Known vascular disease

In addition, risk identification may serve as a wake-up call for patients of concern, eg, those not adhering to medications or otherwise not following their treatment plan.

4myheart®—Personalized Patient Program

The 4myheart® program is a personalized care platform, designed to help your patients improve and maintain heart health. The program is individualized and based on findings from each patient’s Cardio IQ® Test. The service provides access to clinical educators who work with the doctor to create a risk-reduction plan that may help patients improve their heart health. Moreover, the website is redesigned to make it patient-friendly, intuitive, and easy to navigate. Learn more

Test ordering information

Test name

Test code

TEST NAME

Advanced Lipid Panel with Inflammation, Cardio IQ®

Includes: Cardio IQ® Lipid Panel with Reflex to Direct LDL, Cardio IQ® Lipoprotein Fractionation, Ion Mobility, Cardio IQ® Apolipoprotein B, Cardio IQ® Lipoprotein (a), Cardio IQ® hs-CRP, Cardio IQ Lp-PLA2, Cardio IQ® MPO, Cardio IQ® ADMA/SDMA, Cardio IQ® OxLDL, Cardio IQ® F2-Isoprostane/Creatinine

TEST CODE

94220

Lipid Panel/ASCVD (Atherosclerotic Cardiovascular Disease) Risk Panel

TEST NAME

Lipid Panel with Reflex to Direct LDL, Cardio IQ®
Includes:
Cardio IQ® Cholesterol, Total
Cardio IQ® HDL Cholesterol
Cardio IQ® Triglycerides
Cardio IQ® Non-HDL and Calculated Components
If Triglyceride is >400 mg/dL, then Cardio IQ® Direct LDL will be performed
at an additional charge (CPT code(s): 83721).

TEST CODE

92061

TEST NAME

Lipid Panel, Cardio IQ®
Includes:
Cardio IQ® Cholesterol, Total
Cardio IQ® HDL Cholesterol
Cardio IQ® Triglycerides
Cardio IQ® Non-HDL and Calculated Components

TEST CODE

91716

TEST NAME

Cardio IQ® ASCVD Risk Panel with Score
Includes:
Cardio IQ® Cholesterol, Total
Cardio IQ® HDL Cholesterol
Cardio IQ® Triglycerides
Cardio IQ® Non-HDL and Calculated Components
Cardio IQ® Direct LDL
Cardio IQ® ASCVD Risk Scores
If Triglyceride is >400 mg/dL, then Direct LDL will be performed at an additional charge (CPT code(s): 83721).

TEST CODE

92052

Lipoprotein Subfractionation

TEST NAME

Cardio IQ® Lipoprotein Fractionation, Ion Mobility

TEST CODE

91604

TEST NAME

sdLDL

TEST CODE

36406

Apolipoproteins

TEST NAME

Cardio IQ® Apolipoprotein B

TEST CODE

91726

TEST NAME

Cardio IQ® Lipoprotein (a)

TEST CODE

91729

Inflammation

TEST NAME

F2-Isoprostane/Creatinine Ratio

TEST CODE

92771

TEST NAME

OxLDL

TEST CODE

92769

TEST NAME

ADMA/SDMA

TEST CODE

94153

TEST NAME

Cardio IQ® Fibrinogen Antigen, Nephelometry

TEST CODE

91743

TEST NAME

Cardio IQ® hs-CRP

TEST CODE

91737

TEST NAME

Cardio IQ® Lp-PLA2 Activity

TEST CODE

94218

TEST NAME

Cardio IQ® Myeloperoxidase (MPO)

TEST CODE

92814

Metabolic markers

TEST NAME

Cardio IQ® Diabetes Risk Panel with Score

TEST CODE

92026

TEST NAME

Cardio IQ® Glucose

TEST CODE

91947

TEST NAME

Cardio IQ® Hemoglobin A1c

TEST CODE

91732

TEST NAME

Cardio IQ® Insulin

TEST CODE

91731

TEST NAME

Cardio IQ® Homocysteine

TEST CODE

91733

TEST NAME

OmegaCheck®

TEST CODE

92701

TEST NAME

TMAO (Trimethylamine N-Oxide)

TEST CODE

94154

TEST NAME

Cardio IQ® Vitamin D, 25-Hydroxy

TEST CODE

91735

Heart failure

TEST NAME

Cardio IQ® NT ProBNP

TEST CODE

91739

TEST NAME

Cardio IQ® ST2, Soluble

TEST CODE

91823

TEST NAME

Galectin-3

TEST CODE

92768

Genetic cardiovascular markers

TEST NAME

Cardio IQ® 4q25-AF Risk Genotype

TEST CODE

90948

TEST NAME

Cardio IQ® APOE Genotype

TEST CODE

90649

TEST NAME

Cardio IQ® 9p21 Genotype

TEST CODE

90648

TEST NAME

Cardio IQ® CYP2C19 Genotype

TEST CODE

90668

TEST NAME

Cardio IQ® KIF6 Genotype

TEST CODE

90645

TEST NAME

Cardio IQ® LPA Aspirin Genotype

TEST CODE

90553

TEST NAME

Cardio IQ® LPA Intron-25 Genotype

TEST CODE

90655

The Cardio IQ® Enhanced Lab Report offers key insights

Advanced cardiovascular testing provides actionable information to individualize treatment options:

  • Initiate/intensify statin therapy
  • Identify opportunities for adjunct therapy
  • Set diet, exercise, and lifestyle targets

Visit the resource center for additional information on Cardio IQ advanced tests

Heart disease prevention in women

Watch Dr. Felice Gersh, Medical Director at Integrative Medical Group, and Dr. Wohlgemuth, Quest’s Chief Medical Officer, explore the prevalence of heart disease in women and the role of OB/GYNs and lab testing in identifying risk.

Test codes may vary by location. Please contact your local laboratory for more information.

​References:

  1. CDC. Women and heart disease. Reviewed January 31, 2020. Accessed December 10, 2020. https://www.cdc.gov/heartdisease/women.htm
  2. Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke statistics—2018 update: a report from the American Heart Association. Circulation. 2018;137(12): e67-e492. doi:10.1161/CIR.0000000000000558
  3. Sachdeva A, Cannon CP, Deedwania PC, et al. Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines. AmHeartJ. 157(1):111-117.e2. doi:10.1016/j.ahj.2008.08.010
  4. Moore JX, Chaudhary N, Akinyemiju T. Metabolic syndrome prevalence by race/ethnicity and sex in the United States, National Health and Nutrition Examination Survey, 1988–2012. PrevChronicDis. 2017;14:E24. doi:10.5888/pcd14.160287
  5. Konstam MA. Home monitoring should be the central element in an effective program of heart failure disease management. Circulation. 2012;125(6):820-827. doi:10.1161/CIRCULATIONAHA.111.031161

Image content features models and is intended for illustrative purposes only.